Angiogenesis is the process in which new blood vessels are formed which are necessary for the growth of cancer cells. Clover's system attacks this process
Clover Pharma announces today the start of a clinical trial, phase 2, of the drug TL-118 for the treatment of pancreatic cancer. TL-118 is an anti-angiogenic drug, that is, a drug that inhibits the blood supply to cancerous tumors, thereby damaging and neutralizing them.
Following approval from the Ministry of Health, Clover Pharma began a phase 2 trial in three leading oncology centers: Tel Aviv Sourasky Medical Center, Hadassah Medical Center in Jerusalem and soon Sheba Medical Center in Tel Hashomer. 80 patients diagnosed with metastatic pancreatic cancer and who have not yet received chemotherapy will participate in the experiment. The patients will be assigned to one of the two experimental arms, each of which will include 40 patients. The control group will be treated only with the standard chemotherapy for pancreatic cancer and the other group will be treated with TL-118 in addition to chemotherapy.
Dr. Dan Goldstaub, Chief Operating Officer of Clover Pharma, said, "We are very pleased with the results of the animal trial on pancreatic cancer and the initial safety and tolerability results observed in a number of pancreatic cancer patients who have already been treated with TL-118 as part of compassionate care. We look forward to establishing the effectiveness of the product for the treatment of pancreatic cancer in the clinical trial that has just begun."
TL-118 was tested in a model of pancreatic cancer in mice, where exclusive treatment with the drug inhibited the development of the cancerous tumor significantly compared to the standard chemotherapy treatment. Furthermore, treatment with TL-118 in combination with conventional chemotherapy completely eradicated pancreatic tumors in all treated animals.
TL-118 inhibits the formation of new blood vessels (angiogenesis) in tumors and thus inhibits the blood supply to them and their development. The product is given in a drinking solution that is taken once a day, and is a combination of several substances, each of which inhibits the angiogenesis process in a different way and independently of the other substances. All these materials are approved by regulatory authorities. The treatment cycles are well timed in order to allow a user-friendly intake and at the same time a synergistic effect of the ingredients of the preparation for safe and effective cancer treatment. So far over 100 patients have been treated with TL-118 for a period of up to 3 years.
The safety of TL-118 was tested in a phase 1 clinical trial at the Sheba Medical Center in Tel Hashomer. 30 patients participated in the trial, and it was found that the preparation was safe to use and well tolerated by cancer patients, and most of the side effects caused by the treatment were minor.
At the same time, TL-118 is also being tested as a treatment for prostate cancer. So far, about 50 patients have been recruited in Israel for the phase 2 trial, which is under active IND approval granted by the FDA.
Clover Pharma is expected to be included as one of the portfolio companies of Integra Holdings, upon completion of its establishment. Integra Holdings is a new holding company that Yisham, the technology commercialization company of the Hebrew University, is establishing in the field of biotechnology.
About antiangiogenic therapy
Angiogenesis is the process in which new blood vessels are formed which are necessary for the growth of cancer cells. Anti-angiogenic treatments that aim to "starve" the cancer tumor by cutting off the blood supply are a very promising strategy for inhibiting the growth and spread of cancer tumors, because all solid cancer tumors rely on an aggressive process of angiogenesis in order to develop. Unlike cancerous tumors, active angiogenesis does not occur in healthy tissues, which emphasizes the therapeutic potential and feasibility of the anti-angiogenic process. TL-118 was designed to inhibit several parallel, non-overlapping mechanisms involved in angiogenesis.
About pancreatic cancer
6% of cancer deaths in the US are caused by pancreatic cancer. It is the fourth leading cause of death from cancer in women and men in the US. Estimates for 2011 are that 44,000 new cases of pancreatic cancer were diagnosed in the US, and a similar number of deaths occurred in the US this year as a result of pancreatic cancer. The general survival for 5 years for all stages of the disease is only 6% and the expectation for patients with advanced pancreatic cancer is even less.
About Clover Pharma
Clover Pharma is a biotechnology company whose goal is to develop and commercialize its anti-angiogenic platform for the treatment of cancer and other purposes. The company is jointly owned by the Hebrew University of Jerusalem research development company, the company's entrepreneurs, Israeli investors and a Canadian corporation. For more information, visit the company's website www.tiltanpharma.com
9 תגובות
My name is Shiral Cohen, my mother was diagnosed with pancreatic cancer two months ago with a fear of lung infection. I would love to know more things related to the research. And how to join it.
Thanks. This is my mobile 0524054578
My name is Romano Daniel, according to the CT scan they conducted for me, they determined that I have pancreatic cancer in the tail with gliding to the body and metastases in the liver. I would love to know anything related to your research, and if it is possible to take part in it. I will thank you if you contact the registered email, on the English site we have also listed the phone number. Thank you Romano Daniel
My father has pancreatic cancer with metastases to the liver. I would love to receive regular updates.
age:
Maybe change your name to Baruch Jamili?
http://www.youtube.com/watch?v=ZtymP0Qzsts&context=C360a41aADOEgsToPDskKE22L-zfjRJzEeBXjx-u_c
Until now, angiogenic therapies have failed and have not passed the FDA in the treatment of cancer
However, they were successful in the treatment of macular retinal degeneration, which is a 3 times larger market, even though its media coverage is low.
I wish you much success
Was the famous pancreatic cancer patient - Rabbi Yaakov Yosef - included in the experiment?
Agree with Danny's question,
Can other types of cancer be treated with anti-angiogenesis?
Successfully!
If this step is successful, what are the next steps required for the treatment to be accessible to the public?